Lefamulin- Nabriva Therapeutics

Drug Profile

Lefamulin- Nabriva Therapeutics

Alternative Names: BC-3781; BC-3781.Ac; Lefamulin-acetate

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nabriva Therapeutics
  • Class Alkenes; Antibacterials; Cyclopentanes; Diterpenes; Polycyclic compounds; Small molecules; Thioglycolates
  • Mechanism of Action Peptidyltransferase modulators; Protein 50S ribosomal subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia
  • Phase II Skin and soft tissue infections
  • Preclinical Bacterial infections; Bone and joint infections; Nosocomial pneumonia; Osteomyelitis; Sexually transmitted infections

Most Recent Events

  • 04 Dec 2017 Nabriva Therapeutics completes enrolment in the phase III LEAP 2 trial for Community acquired pneumonia in USA, Argentina, Brazil, Bulgaria, Chile, Georgia, Latvia, Mexico, Peru, Philippines, Poland, Romania, Russia, Serbia, South Africa, South Korea, Taiwan and Ukraine (NCT02813694)
  • 15 Nov 2017 Lefamulin is still in preclinical development for Sexually transmitted infections in USA (PO, Tablet) (IV, Infusion) (Nabriva Therapeutics pipeline, November 2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Community-acquired-pneumonia(In volunteers) in Austria (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top